MD Capital Advisors is working with a leading urology company that is founded by seasoned entrepreneurial professionals who spent time with leading companies such as Boston Scientific, Alcon Surgical and Amgen and enjoys clinical support from leading academic medical centers.
The urology company is an innovative medical device company with proprietary technology for BPH (enlarged prostate) and has developed a surgical device and procedure that reduces the prostate and spares the urethra. The company’s proprietary technology eliminates the well known pain and complications associated with traditional surgical approaches by alleviating the “obstructive outflow” associated with an enlarged prostate, and eliminating the need for lifelong pharmaceutical therapies such as Flomax. The company believes that the “spare the urethra” approach and potential lower risk and complications of the procedure will meet with great market demand.
BPH global market has 500+ million potential customers / patients.
This is not a solicitation to invest. Additional information and company video available upon execution of a Non-Disclosure Agreement (NDA). For further information, please contact MD Capital Advisors.